Development of a Novel BifurcAID Risk Score to Predict Major Adverse Cardiovascular Events (MACE) Following Coronary True Bifurcation Intervention
Authors' conclusion
The BifurcAID risk score may facilitate risk stratification among patients undergoing true bifurcation PCI and guide patient-tailored treatment strategies.
Study context
- Population
- Consecutive patients undergoing percutaneous coronary intervention (PCI) for true bifurcation lesions, 2012–2019, single institution
- Participants
- 1,896 consecutive patients
- Exposure
- BifurcAID risk categories: intermediate and high vs low risk
- Outcome
- MACE:
- All-cause death
- MI
- Target vessel revascularization
- Follow-up
- 1 year
Methodological detailssingle-centre, risk score development, independent core laboratory
- Single-centre
- Risk score development
- Independent core laboratory
Main finding
As reported in the abstract
MACE by risk category
Each group vs low riskOdds ratio (95% CI)P value
Intermediate risk
2.63(1.74–3.98)
P < 0.001High risk
5.18(3.56–7.53)
P < 0.001Observational data: associations, not effects.
Further findings
Overall 1-year MACE
- MACE in 185 patients
- 9.8%
Predictors of MACE
- Clinical predictors: insulin-dependent DM, LVEF ≤30%, NSTEMI presentation, age >80 years, non-white race/ethnicity
- 5
- Angiographic predictors: left main or left circumflex-obtuse marginal lesion, multivessel disease, side branch thrombus, side branch moderate/severe calcium, side branch lesion length >10 mm
- 6
- Eleven predictors in total
Original publication
Development of a Novel BifurcAID Risk Score to Predict MACE Following Coronary True Bifurcation Intervention. JACC Cardiovasc Interv. Published 24 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →